Cagrilintide
10mg
⚠️ Not for human consumption. Research purposes only.
Description
Cagrilintide is a long-acting acylated amylin-receptor agonist investigated in preclinical and clinical-phase metabolic research. Peer-reviewed data characterize its binding kinetics at calcitonin and amylin receptor subtypes (CTR/RAMP complexes), with downstream effects on gastric motility, area postrema signaling, and glucagon suppression in rodent and primate models. Supplied as a 10mg lyophilized vial for in vitro and in vivo laboratory use only.
Key Areas of Study
- Amylin receptor binding kinetics research
- area postrema signaling pathway studies
- gastric motility modulation analysis
- glucagon suppression modeling
Mechanisms Being Evaluated
Engages calcitonin receptor/RAMP heterodimer complexes with extended half-life due to albumin-binding acyl chain modification. Preclinical models demonstrate modulation of area postrema neuronal firing, delayed gastric emptying via vagal efferent pathways, and suppression of pancreatic alpha-cell glucagon secretion.
Commonly Researched Uses
Amylin receptor pharmacology research, area postrema signaling studies, gastric motility modeling, combination incretin-receptor agonist interaction studies in preclinical settings
Recent Studies and Trials
The following peer-reviewed studies and clinical trials have investigated the properties and applications of this peptide:
Cagrilintide Plus Semaglutide for Weight Management
Published: 2021
Amylin Analog Effects on Appetite and Body Weight
Published: 2021
Phase 2 Trial of Cagrilintide in Obesity
Published: 2021
Note: These studies are provided for informational and research purposes only. This product is not intended for human consumption.